To ask the Scottish Executive when it intends to make cetuximab freely available across the national health service in Scotland. (S3O-1248)
Official Report · Chamber
Cetuximab
SCOTTISH EXECUTIVE Health and Wellbeing
Speakers
Choose an MSP to read only their contributions- Nicola Sturgeon SNP 4
- Bill Butler Lab 2
- Rob Gibson SNP 1
- Peter Peacock Lab 1
- Alex Fergusson 1
The record
9 contributions
Nicola Sturgeon
SNP The Deputy First Minister and Cabinet Secretary for Health and Wellbeing · Glasgow Govan
link
The Scottish medicines consortium has considered cetuximab for use in the treatment of certain conditions. I expect NHS boards and clinicians to take full account of the SMC's recommendations in the decisions they make. When drugs are recommended, I expect them to be made available in line with that advice.
The minister will be aware that a number of my constituents have been in touch with me about the drug because I have written to her on the general issue and on the case of a particular individual. I understand that, in exceptional circumstances, health boards can review whether specific treatments should be provided. It is also my understanding that patients in Wales can access the drug on the NHS.
As the cabinet secretary will probably know, the leading charity Bowel Cancer UK believes that proof of the efficacy and benefits of the treatment is growing all the time, especially for people in the later stages of the disease. Given the stark consequences for the individuals involved and their families and friends, will she assure us that she will do everything in her power to ensure that health boards are provided with the necessary resources to allow cetuximab to be made available to those who are in most need of it? Will she assure us that decisions will be made solely on the basis of clinical and medical need and will not be coloured by any financial considerations?
As the cabinet secretary will probably know, the leading charity Bowel Cancer UK believes that proof of the efficacy and benefits of the treatment is growing all the time, especially for people in the later stages of the disease. Given the stark consequences for the individuals involved and their families and friends, will she assure us that she will do everything in her power to ensure that health boards are provided with the necessary resources to allow cetuximab to be made available to those who are in most need of it? Will she assure us that decisions will be made solely on the basis of clinical and medical need and will not be coloured by any financial considerations?
Nicola Sturgeon
SNP The Deputy First Minister and Cabinet Secretary for Health and Wellbeing · Glasgow Govan
link
I thank Bill Butler for the constructive way in which he asked his question. I am very aware of the case to which he refers—as a result of his correspondence and following representations from Richard Lochhead, who is the individual's constituency MSP. I have enormous sympathy for the position in which the individual finds himself. None of us can fully appreciate what he is going through.
This is an extremely serious and difficult matter. I hope that everyone in the chamber, regardless of their political persuasion—this is not a political issue—appreciates that it is essential to have in place a system for approving new drugs, and that that system must be expert led and evidence based. In Scotland, the process is conducted primarily through the Scottish medicines consortium. New evidence will always be considered, because it is vital that decisions should always be taken on a clinical basis. Everyone in the chamber will agree that it would be invidious and totally wrong for decisions about what drugs can be prescribed and to whom they should be prescribed to be taken by politicians. None of us wants that situation to develop.
I confirm that, when the Scottish medicines consortium has not approved a drug, it is open to any clinician to put the argument to a health board that a particular patient is an exceptional case. That underlines the assurance that I give Bill Butler that such decisions will always be taken on clinical grounds.
This is an extremely serious and difficult matter. I hope that everyone in the chamber, regardless of their political persuasion—this is not a political issue—appreciates that it is essential to have in place a system for approving new drugs, and that that system must be expert led and evidence based. In Scotland, the process is conducted primarily through the Scottish medicines consortium. New evidence will always be considered, because it is vital that decisions should always be taken on a clinical basis. Everyone in the chamber will agree that it would be invidious and totally wrong for decisions about what drugs can be prescribed and to whom they should be prescribed to be taken by politicians. None of us wants that situation to develop.
I confirm that, when the Scottish medicines consortium has not approved a drug, it is open to any clinician to put the argument to a health board that a particular patient is an exceptional case. That underlines the assurance that I give Bill Butler that such decisions will always be taken on clinical grounds.
Members will have seen the widespread publicity about our constituent, Michael Gray, and the letters that we have received from many of his friends. It is concerning that, while a trial for cetuximab has been taking place in Aberdeen, it has not yet been possible for Mr Gray to benefit from the drug. Can the cabinet secretary help us in this case—and more widely—by telling us how bowel cancer policy nationally will cope with the development of science and the interventions that will be required, despite what some of those may cost initially?
Nicola Sturgeon
SNP The Deputy First Minister and Cabinet Secretary for Health and Wellbeing · Glasgow Govan
link
Tackling cancer generally, and bowel cancer in particular, is a key priority for the Government. We are in the process of rolling out bowel cancer screening across the country. That has the potential to save many lives. It may also lead to more cases being diagnosed earlier, which places an obligation on us to ensure that the necessary treatment and services are available. I assure the chamber that the Government places the highest possible priority on giving the best possible services to cancer sufferers. That is why I have made it such a personal priority to meet the 62-day waiting time target for cancer patients.
As I said to Bill Butler, the process that we have, which is the right process, will inevitably lead to very difficult and, often, painful decisions. I appreciate the personal trauma that that will cause individuals in particular cases, but it is essential that an evidence-based, expert-led system is in place, as is the case in Scotland. If new evidence emerges on any drug—cetuximab has been assessed by the Scottish medicines consortium on two occasions—it will be considered by the SMC, as is right and proper.
As I said to Bill Butler, the process that we have, which is the right process, will inevitably lead to very difficult and, often, painful decisions. I appreciate the personal trauma that that will cause individuals in particular cases, but it is essential that an evidence-based, expert-led system is in place, as is the case in Scotland. If new evidence emerges on any drug—cetuximab has been assessed by the Scottish medicines consortium on two occasions—it will be considered by the SMC, as is right and proper.
As Nicola Sturgeon said, these are difficult issues. I am disappointed that her response was not more encouraging, but I would like to push her further on the issue. In the case to which she and Rob Gibson have referred—and to which Richard Lochhead cannot refer because he is a minister—it appears that NHS Grampian is prepared to fund the use of cetuximab when it is believed that, in his or her particular circumstances, a patient might benefit more from it than is the norm. That is an extraordinarily fine judgment for a consultant to have to make. Until the drug is tried, it is not possible to say definitively that a patient would not benefit more than other, similar, patients would. The only way of getting any equity and justice in that situation is to ensure that the drug is available when the consultant believes that it should be; I gather that that is the case in this instance.
In the case that we are discussing, there is literally no time to spare. I urge the cabinet secretary to refer the matter back to the SMC, in the light of the changing evidence to which Bill Butler referred, and to do so without delay.
In the case that we are discussing, there is literally no time to spare. I urge the cabinet secretary to refer the matter back to the SMC, in the light of the changing evidence to which Bill Butler referred, and to do so without delay.
Nicola Sturgeon
SNP The Deputy First Minister and Cabinet Secretary for Health and Wellbeing · Glasgow Govan
link
Rightly, the SMC is an independent body. It will consider new evidence as new evidence emerges: it does so all the time. In my answer to Bill Butler, I made it clear that there is a process for dealing with situations in which the SMC has not approved a drug: individual clinicians who believe that individual patients are exceptional cases put that argument to the NHS board in question. I appreciate that that requires clinicians to make fine judgments, but I believe more than anything that those are clinical judgments, not judgments that politicians should try to make.
NHS Grampian is very aware of the case and will be aware of developments. We all have the most enormous sympathy for the predicament of the individual involved. Such cases are always difficult and painful, but we must have in place a system that is evidence based and expert led—and that is what we have. In such a system, new evidence will always be considered.
NHS Grampian is very aware of the case and will be aware of developments. We all have the most enormous sympathy for the predicament of the individual involved. Such cases are always difficult and painful, but we must have in place a system that is evidence based and expert led—and that is what we have. In such a system, new evidence will always be considered.
Alex Fergusson
The Presiding Officer · Galloway and Upper Nithsdale
link
Question 3 has been withdrawn.
In this meeting
Everything on 15 Nov 2007 →- Scottish Parliament Thursday 15 November 2007 Debate · 1
- Scottish Legal Services Market Debate · 35
- SCOTTISH EXECUTIVE Questions · 1
- Fire Sprinklers (Regulations) Questions · 4
- Water and Sewerage Services (Charges) Questions · 6
- Tourist Information Centres Questions · 17
- Economic Development (Fife) Questions · 6
- Education Questions · 7
- Engagements First Minister’s Questions · 10
- Prime Minister (Meetings) First Minister’s Questions · 8
- Cabinet (Meetings) First Minister’s Questions · 17
- Proceeds of Crime Act 2002 First Minister’s Questions · 8
- Police (Funding) First Minister’s Questions · 14
- Nursery Teachers First Minister’s Questions · 10
- British Red Cross (Financial Support) Questions · 7
- Cetuximab Questions · 9
- Childhood Obesity Questions · 6
- Scottish Diabetes Framework Action Plan Questions · 6
- Warm Deal Questions · 5
- Foot-and-mouth Disease (Interim Payments) Questions · 8
- Flooding and Coastal Erosion (Forth Estuary) Questions · 4
- Sustainable Development (Carbon Emissions) Questions · 8
- Animal Rendering (Capacity) Questions · 4
- Biodiversity Questions · 4
- Environmental Organisations (Meetings) Questions · 4
- Pig Industry Questions · 4
- Abolition of Bridge Tolls (Scotland) Bill: Stage 1 Bill debate · 93
- Point of Order Procedure · 10
- Abolition of Bridge Tolls (Scotland) Bill: Financial Resolution Bill debate · 4
- Decision Time Decision time · 22
- Alcohol and Tobacco Consumption Members’ business · 11
The type of each item (debate, statement, questions, members’ business and so on) and the times shown are worked out by this site from headings, the chair’s opening words and the Official Report’s running timestamps. They are not the Parliament’s own classification. Text: the Scottish Parliament Official Report.